Table 2.
Overall survival (OS), event free survival (EFS) and current event free survival (cEFS) at 30 years by age, decade, primary treatment and severity
| OS | EFS | CEFS | |
|---|---|---|---|
| Primary treatment | |||
| Allo HCT | 43 (+ 14)% | 37 (+ 13)% | 41 (+ 15)% |
| IST | 40 (+ 9)% | 29 (+ 8)% | 41 (+ 9)% |
| p-value | 0.177 | 0.888 | 0.301 |
| Age | |||
| <18 | 34 (+ 14)% | 32 (+ 10)% | 32 (+ 15)% |
| 18-40 | 51 (+ 13)% | 35 (+ 11)% | 49 (+ 13)% |
| 40-60 |
32 (+ 21)% (at 25 years) |
20 (+ 20)% (at 25 years) |
33 (+ 24)% (at 25 years) |
| > 60 |
18 (+ 20)% (at 20 years) |
30 (+ 18)% (at 15 years) |
31 (+ 23)% (at 25 years) |
| p-value | 0.049 | 0.597 | 0.096 |
| Decade | |||
| 70s | 22 (+ 12)% | 18 (+ 12)% | 22 (+ 12)% |
| 80s | 44 (+ 11)% | 36 (+ 10)% | 44 (+ 11)% |
| 90s |
51 (+ 18)% (at 20 years) |
42 (+ 16)% (at 20 years) |
27 (+ 39)% |
| 00s |
53 (+ 18)% (at 13 years) |
27 (+ 16)% (at 13 years) |
55 (+ 17)% (at 13 years) |
| 10s |
71 (+ 18)% (at 4 years) |
50 (+ 18)% (at 5 years) |
71 (+ 18)% (at 5 years) |
| p-value | 0.003 | 0.084 | 0.021 |
| Severity | |||
| VSAA | 15(+ 23)% | 28 (+ 14)% | 34 (+ 16)% |
| SAA | 48 (+ 12)% | 32 (+ 10)% | 43 (+ 12)% |
| NSAA | 41 (+ 14)% | 34 (+ 14)% | 21 (+ 31)% |
| p-value | 0.073 | 0.623 | 0.190 |
Data presented as Kaplan Meier estimate and 95% confidence interval.